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Abstract. Breast cancer is the most common type of cancer 
in females in Argentina, with an incidence rate similar to 
that in the USA. However, the contribution of the BRCA1 or 
BRCA2 mutation in breast cancer incidence has not yet been 
investigated in Argentina. In order to evaluate which BRCA1 
polymorphisms or mutations characterize female breast 
cancer in Argentina, the current study enrolled 206 females 
with breast cancer from several hospitals from the southeast 
of Argentina. A buccal smear sample was obtained in dupli-
cate from each patient and the DNA samples were processed 
for polymorphism analysis using the single-strand confor-
mational polymorphism technique. The polymorphisms in 
BRCA1 were investigated using a combination of 15 primers 
to analyze exons 2, 3, 5, 20 and 11 (including the 11.1 to 11.12 
regions). The BRCA1 mutations were confirmed by direct 
sequencing. Samples were successfully examined from 
154 females and, among these, 16 mutations were identi-
fied in the BRCA1 gene representing 13.9% of the samples 
analyzed. One patient was identified with a polymorphism 
in exon 2 (0.86%), four in exon 20 (3.48%), four in exon 11.3 
(3.48%), one in exon 11.7 (0.86%), two in exon 11.8 (1.74%), 
one in exon 11.10 (0.86%) and one in exon 11.11 (0.86%). 
The most prevalent alteration in BRCA1 was located in 
exon 11 (11 out of 16 patients; 68.75%). The objective of our 
next study is to evaluate the prevalence of mutations in the 
BRCA2 gene and analyze the BRCA1 gene in the healthy 
relatives of BRCA1 mutation carriers.
Introduction
Breast cancer is the most prevalent and leading cause of 
mortality among females worldwide. Through epidemiolog-
ical studies, it has been found that family history is one of the 
major risk factors that increases susceptibility to breast cancer. 
Approximately 5‑10% of breast cancers have a hereditary 
component (1), and inherited mutations in high penetrance 
genes, such as BRCA1 and BRCA2 (2), closely correlate with 
an increased risk of females of different ethnic and age groups 
developing breast and/or ovarian cancer (1). In addition, such 
mutations in the germline increase the susceptibility to develop 
cancer of the colon, prostate, pancreas and melanoma (2). It is 
evident that these mutations are involved in a small fraction of 
all cancers detected and the presence of sequence alterations 
in the BRCA genes has significant clinical relevance.
Mutations in the BRCA1 and BRCA2 genes are trans-
mitted from one generation to the next by an autosomal 
dominant (3). The germline mutations are usually point 
mutations (4) and are commonly frameshift small insertions 
or deletions, non-sense mutations, or mutations affecting the 
splicing sites (2). The majority of these mutations identified 
in familial breast cancer result in the partial or complete 
deletion of exons or intronic sequence inserts, which may ulti-
mately yield non-functional, truncated BRCA1 and BRCA2 
proteins (2). Approximately 50% of these mutations are 
located within exon 11 of BRCA1 and BRCA2 (5). Females 
who carry mutations in the BRCA1 gene have an 80% chance 
of developing breast cancer during their lifetime, and a 65% 
chance of developing a second breast cancer prior to the age 
of 70 years. Similarly, females with BRCA2 mutations have an 
85% chance of developing breast cancer (6).
BRCA1 and BRCA2 are structurally similar and of similar 
size (100 and 70 Kb, respectively) (4). The two genes are 
considered to be tumor suppressor genes. BRCA1 is located 
on chromosome 17 at the q21 position and consists of 22 exons 
(60% of the gene corresponding to exon 11) that encode a 
protein of 1,863 amino acids (7,8). Due to its large size, exon 11 
is the main target for mutation detection. BRCA2 is located on 
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chromosome 13 at the 12q position and consists of 27 exons 
that encode a protein of 3,418 amino acids (9,10).
Functionally, BRCA1 and BRCA2 are involved in a multi-
tude of cellular processes, such as transcriptional regulation 
in response to DNA damage, maintenance of chromosomal 
stability and the regulation of genes involved in the cell cycle 
and apoptosis (11).
In total, >600 mutations have been described in BRCA1, 
while 450 mutations have been described in BRCA2 (6). 
Approximately 50% of the unique variants detected in BRCA1 
and BRCA2, regardless of the polymorphisms, are variants 
with unknown pathogenic potential and are thus termed 
unclassified variants (2). It is also possible to identify variants 
of unknown significance. These are variations in the gene 
sequence which have not been identified to affect the func-
tion of the protein. It is possible that polymorphisms of the 
two genes may result in loss of protein function and thereby 
increase the risk of cancer; however, the polymorphisms may 
also exist without risk (12).
The aim of this study was to differentiate between harm-
less deleterious mutations and polymorphisms in the BRCA1 
gene of 154 females with breast cancer in the city of Bahía 
Blanca in Argentina, as well as cities in close proximity to 
Bahía Blanca. To the best of our knowledge, this is the first 
study in Argentina to detect variations in the BRCA1 gene.
Materials and methods
Study approval. The study was approved by the research 
ethics committees of the South Regional Italian Hospital 
(Bahía Blanca, Argentina), FEMALE Medical Institute 
MEDIFEM (Bahía Blanca, Argentina), Lavalle Institute of 
Diagnostics (Bahía Blanca, Argentina), Dr Leonidas Lucero's 
Hospital (Bahía Blanca, Argentina), Viedma Clinic (Viedma, 
Argentina), Lucio Molas's Hospital (Santa Rosa, Argentina) 
and Pigue Municipal's Hospital (Pigue, Argentina), and 
written informed consent was provided by all patients prior to 
voluntarily participating in this study.
Sampling. For this study, 154 female patients (age 
range, 38‑67 years), with breast cancer at any stage of disease, 
with or without familial breast cancer history, and with or 
without cancer treatment, but had undergone breast surgery 
were included. From each patient, buccal mucosa cells were 
obtained from the patients via a cheek swab performed by the 
doctors responsible for the study in their respective hospitals. 
Samples were collected in duplicate for analysis. To avoid 
inadequate samples, the patients were required to fast for 
6-8 h, have good oral hygiene and to rinse the mouth several 
times with water prior to sampling. In addition, the adminis-
tration of drugs prior to sampling was prohibited, to prevent 
interference with the subsequent analysis. The doctor who 
performed the sampling used two swabs simultaneously to 
achieve a duplicate sample. The sterile swabs (Cole-Parmer, 
Vernon Hills, IL, USA) were removed from their packaging 
and rubbed firmly and several times on the bilateral buccal 
mucosa of the patient. The swabs were then air-dried for 
15 min, and sent to the laboratory (Breast Cancer Research 
Laboratory, CERZOS-CONICET, Bahía Blanca, Argentina)
within 24 h. The buccal swab samples were kept dry and 
protected from light at room temperature. The first swab was 
used for the isolation of DNA, while the second swab was kept 
in the aforementioned conditions for later use if required.
Extraction of the genomic DNA. DNA was extracted from the 
buccal mucosa cells using a commercial kit for genomic DNA 
isolation (Nexttec™ 1-step DNA Isolation; Nextec Applications, 
Inc., Greenwich, CT, USA). The commercial kit included all the 
reagents required for the lysis of the cells and purification of 
the DNA. The aim of the protocol was to retain the proteins, 
detergents and components of low molecular weight on the 
resin column, allowing the passage of the DNA through the 
column. The DNA extracted from the buccal swab samples was 
preserved in a freezer at -20˚C.
Quality control and semi‑quantitation of DNA. The concen-
tration and quality of the DNA obtained using the isolation kit 
purchased from Nextec Applications, Inc. was analyzed by gel 
electrophoresis in 1.5% agarose at 80 V for 2 h. Subsequently, 
the gel was stained with ethidium bromide and the bands were 
displayed on an ultraviolet transilluminator (FOTO/UV® 21 
FOTODYNE 312 nm DNA transilluminators; Fotodyne 
Incorporated, Hartland, WI, USA). A molecular weight marker 
was used in each run. The isolated DNA concentration was 
determined by comparing the fluorescence intensity between 
the weight marker of a known concentration and DNA bands 
of unknown concentration. The integrity of the bands was the 
parameter used to evaluate the quality of the isolated DNA.
Selection of primers and nucleotide sequence. The 
single-strand conformational polymorphism (SSCP) technique 
was employed to analyze exons 2, 3, 5, 20 and 11 of the BRCA1 
gene. Considering the large size of exon 11, and in order to 
analyze it in its entirety, the exon was divided into 12 over-
lapping fragments. The primers were selected according to 
a previous study in the Brazilian literature investigating the 
frequency of mutations in these regions of the BRCA1 gene in 
females of the Latino population (6).
Fragment amplification by polymerase chain reaction (PCR). 
Each PCR was performed using 50 ng of DNA, 1X PCR Buffer 
with 1.5 mM MgCl2 (Amersham Biosciences, Piscataway, NJ, 
USA), 200 µM dNTPs (Amersham Biosciences), 10 µM of 
each primer (see Table I) and 1 unit of Taq DNA polymerase 
(Amersham Biosciences) in a final volume of 12.5 µl. The PCR 
protocol used was the same for each amplified gene region with 
the exception of the annealing temperature, which was speci-
fied by each primer pair. The amplification conditions were as 
follows: Initial denaturalization for 5 min at 96˚C; 35 cycles 
of 30 sec at 96˚C and 30 sec at the annealing temperature 
(annealing) of each pair of primers; 1 min for elongation at 
72˚C; and a final extension for 10 min at 72˚C. The samples 
were maintained at 4˚C until removal from the thermocycler.
SSCP fragment separation in denaturing polyacrylamide gel. 
The PCR products were diluted 3:1 in 3X Loading buffer 
(0.5 M EDTA, 95% formamide and 0.05% bromophenol blue; 
Promega Corporation, Madison, WI, USA). The PCR products 
denatured at 98˚C for 10 min and immediately placed on ice to 
allow the fragments of ssDNA to fold into three-dimensional 
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structures as a result of intrastrand base pairing. The gel 
running conditions were as follows: 700 V and 17 Watt for 11 h 
at room temperature. To visualize the resulting band pattern of 
the electrophoretic run, the gel was stained with silver nitrate 
and revealed with sodium carbonate.
Polymorphism confirmation. All polymorphisms detected 
in the acrylamide gel were confirmed by repeating the PCR 
reaction, subsequently employing the genetic material isolated 
from the preserved second swab. Next, the reaction was 
repeated using DNA obtained from the peripheral blood of 
each patient to sequence and determine the type of mutation 
existing in the polymorphic region.
Sequencing of the polymorphism SSCP products. The PCR 
products with abnormal bands (polymorphisms) in the elec-
trophoretic pattern of the SSCP were sent to Ruralex Fagos 
(Buenos Aires, Argentina) for sequencing. The sequencing 
was performed using the dideoxy method using the terminal 
chain method and Big Dye® technology (Applied Biosystems, 
Foster City, CA, USA). The primers used for sequencing were 
the same as those used for the PCR reaction. The cycling 
conditions were as follows: 96˚C for 5 min; 35 cycles of 30 sec 
at 94˚C, 30 sec at 51˚C and 4 min at 60˚C; followed by a cycle 
of 10 min at 60˚C. The amplification products were puri-
fied using a protocol based on MgCl2/ethanol and run on an 
ABI 310 genetic analyzer (Applied Biosystems). The results 
were analyzed using ABI PRISM® 3100-Avant and 3100 Data 
Collection v2.0 software (Applied Biosystems).
Results
Analysis was performed on a total of 154 DNA samples 
obtained from females with breast cancer, with or without 
a family history. Exons 2, 3, 5, 20 and 11 (including the 11.1 
to 11.12 regions) of the BRCA1 gene were analyzed. These 
Table I. BRCA1 gene primer nucleotide sequences for single-strand conformational polymorphism analysis.
Exon no. Nucleotide sequence Annealing temperature, ˚C
  2 F: GAA GTT GTC ATT TTA TAA ACC TTT 57
  R: TGT CTT TTC TTC CCT AGT ATG T 57
  3 F: TCC TGA CAG AGC AGA CAT TTA 53
  R: TTG GAT TTT CGT TCT CAC TTA 53
  5 F: CTC TTA AGG GCA GTT GTC AG 58
  R: TTC CTA CTG TGG TTG CTT CC 58
20 F: ATA TGA CGT GTC TGC TCC AC 57
  R: GGG AAT CCA AAT TAC ACA GC 57
11.1 F: CCA AGG TGT ATG AAG TAT GT 57
  R: GAT CAG CAT TCA GAT CTA CC 57
11.2 F: CTC ACT AAA GAC AGA ATG 56
  R: CTT TCT GAA TGC TGC TAT 56
11.3 F: CAG AAA CTG CCA TGC TTC AGA 56
  R: AGG CTT GCC TTC TTC CGA TA 56
11.4 F: GTT CAC TCC AAA TCA GTA GAG AG 56
  R: CAG CTT TGC TTT TGA AGG CAG 56
11.5 F: CCT AAC CCA ATA GAA TCA CTC G 56
  R: GAA CCA GGT GCA TTT GTT AAC TTC 56
11.6 F: CAG CGA TAC TTT CCC AGA GC 56
  R: GTC CCT TGG GGT TTT CAA A 56
11.7 F: CTG GAA GTT AGC ACT CTA GG 56
  R: GTT GCA CAT TCC TCT TCT GC 56
11.8 F: CCG TTT TCA AAT CCA GGA AA 56
  R: TGA TGG GAA AAA GTG GTG GT 56
11.9 F: GAG GCA ACG AAA CTG GAC TCA 56
  R: CTC AGG TTG CAA AAC CCC TA 56
11.10 F: AAC AGA GGG CCA AAA TTG AA 56
  R: GGG TGA AAG GGC TAG GAC TC 56
11.11 F: AAA GCG TCC AGA AAG GAG AGC 56
  R: GCC TTT GCC AAT ATT ACC TGG 56
11.12 F: CAT TGA AGA ATA GCT TAA ATG 56
  R: CCT GGT TCC AAT ACC TAA GTT 56
F, forward; R, reverse.
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Figure 2. cDNA sequencing of exon 11.11 of the BRCA1 gene. The SSCP-polyacrylamide gel electrophoresis was compared with the SSCP product 
sequencing of BRCA1 exon 11.11 obtained from patient 28 at the South Regional Italian Hospital (Bahìa Blanca, Argentina). The left figure shows a 
polymorphism in BRCA1 exon 11.11 which was not identified in the control, the central figure shows the nucleotide sequencing of the SSCP region and the 
right figure shows the polymorphism identified in the nucleotide 3,674 from exon 11.11 of the BRCA1 gene, corresponding to a single change from guanine 
to cytosine. SSCP, single-strand conformational polymorphism.
Table II. Prevalence of BRCA1 gene polymorphisms detected in 154 breast cancer patients from the south region of Argentina.
 Polymorphisms detected
 -----------------------------------------------------------------------------------------------------------------------------------------------------------
Exon no. Patients with alterations, n General prevalence, %
  2   1   0.69
20   4   2.76
11.1   2   1.38
11.3   4   2.76
11.5   2   1.38
11.7   1   0.69
11.8   2   1.38
11.10   1   0.69
11.11   1   0.69
11.12   3   2.07
Total 21 14.49
Figure 1. BRCA1 gene polymorphisms detected in 21 out of 154 breast cancer patients using the SSCP method. Images of the SSCP products run in the poly-
acrylamide non‑denaturing gel and developed with silver nitrate. BRCA1 polymorphisms were identified in the following exons of the breast cancer patients 
(identification number indicated in the figure): 2, 20, 11.1, 11.3, 11.5, 11.7, 11.8, 11.10, 11.11 and 11.12. In each gel, the control column was run in parallel with 
the sample, corresponding to a normal healthy patient without breast cancer. SSCP, single-strand conformational polymorphism.
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exons were selected as several studies have shown increased 
mutagenic frequency in these regions (13-18). Following 
sampling of the buccal mucosa and subsequent extraction 
of the DNA as previously described, the SSCP technique 
was performed based on the separation of the DNA frag-
ments according to their three dimensional conformation in 
non-denaturing polyacrylamide gels. The DNA of an indi-
vidual without breast or ovarian cancer was used to identify 
the altered electrophoretic pattern in patients with cancer. In 
the full analysis, 21 possible polymorphisms were detected; 
one in exon 2, four in exon 20, two in exon 11.1, four in 
exon 11.3, two in exon 11.5, one in exon 11.7, two in exon 11.8, 
one in exon 11.10, one in exon 11.11 and three in exon 11.12 
(Fig. 1, Table II). Overall, 76.20% of the altered electro-
phoretic activity was identified within exon 11, as predicted 
given its large size. Of these possible polymorphisms, three 
were confirmed by performing the full analysis process using 
the second preserved swab. Subsequently, peripheral blood 
was extracted from the patients whose results had shown 
an altered electrophoretic pattern. The DNA was extracted 
and the samples were sent for sequencing. The samples were 
sequenced and two indeterminate results were obtained; one 
a missense mutation of a G to C change at position 3,674 
corresponding to exon 11.11 of the BRCA1 gene (Fig. 2).
Discussion
It has been reported that ~0.1% of the population possess a total 
of 5,000 different BRCA gene mutations (19). Collaboration 
among medical professionals and researchers is required to 
gain increased knowledge concerning the mutational spectrum 
and ethnic distribution of the different mutations (1). It is also 
important to establish the pattern of breast cancer risk in the 
population associated with a given mutation. This may clarify 
the mechanism responsible and allow the proper precautions 
to be taken (14).
It is important to identify females at high risk of developing 
breast cancer. Inheriting a deleterious BRCA mutation is one 
of the most important predictors of individual risk (15). Only 
10% of all breast cancers are hereditary and, as previously 
described, <1% of the population carry BRCA gene mutations. 
BRCA mutations are associated with a relative increase of 
2.7‑6.4 times the risk of breast cancer, as well as an increased 
risk of ovarian cancer of 9.3‑35.3 times the average risk. 
Females who carry a deleterious mutation in the BRCA genes 
may be offered chemoprevention, such as early surveillance 
and prophylactic surgery. Health professionals should increase 
patient understanding of the risk of mutations in the BRCA 
genes. It is also important to promote public policies through 
adherence of the female population to preventive strategies, 
thus reducing the morbidity and mortality associated with 
hereditary cancers (20).
As previously described, being a carrier of a BRCA gene 
mutation is associated with an increased risk of certain types 
of cancer, particularly breast and ovarian cancer. However, 
individuals with a family history of BRCA mutations may not 
carry the mutation and a negative result may be misleading. 
Therefore, in this study, patients suffering from cancer were 
employed as the priority group, as these patients have an 
increased chance of having a BRCA1 gene alteration than 
healthy females without breast cancer. Although the results 
of genetic analysis may be normal or without alterations, 
the patient may have mutations in other regions of the gene 
which were not analyzed or in other genes associated with 
the BRCA genes. Notably, the presence of mutations in the 
BRCA genes in females with primary breast cancer indicates a 
higher chance of developing a second cancer in another organ, 
bilateral breast cancer or recurrence of the cancer in the same 
breast. In addition, healthy relatives may also carry the same 
genetic alteration in the BRCA1 gene and, therefore, have a 
significantly higher risk of developing the disease than the 
general population.
A recent study has yielded encouraging results on the devel-
opment of a test gene expression profile from the peripheral 
blood for the early detection of breast cancer with a predic-
tion accuracy of 79.5%, sensitivity of 80.6% and specificity of 
78.3% (21).
It is extremely important to perform genetic analysis for 
BRCA mutations in patients at a high risk of developing breast 
cancer in Argentina to aid health professionals in addressing the 
prevention, treatment and prognosis of the disease (1,4). However, 
such studies have been limited to a small sample size in BRCA1 
mutation analysis and, therefore, the current study performed 
this screening with a large sample size of 154 patients.
The social impact of this study could be important as, 
to the best of our knowledge, similar studies have not be 
performed in Argentina. The majority of the studies conducted 
in different countries differ in their results for the pathological 
features of patients with breast cancer associated with the type 
of BRCA1 gene mutation. However, these tumors tend to be of 
high grade, and less frequently express the estrogen receptor 
(ER) or progesterone receptor (PR), which have been associ-
ated with a poor prognosis in sporadic tumors. The aim of the 
present study was to determine whether there is a correlation 
between the type of alteration found in BRCA1 and the histo-
logical subtype, which may also be useful for determining 
the association between the expression of hormone receptors, 
such as ER, PR and HER2, that were analyzed in all patients 
included in this study. In addition, this study is important to 
report the genetic variations in Argentinian females and to 
examine similarities with the world population.
The social impact of this project may also be important for 
the prevention and early diagnosis of breast cancer, which are 
essential to patients carrying mutations in the BRCA 1/2 gene, 
to select the best and most appropriate method of prevention 
for the development of breast cancer, including prophylactic 
breast surgery or risk reduction strategies. It is also important 
to note that a healthy person possessing a mutation may not 
develop the disease, but is at a higher risk of developing breast 
cancer. At present, the use of prophylactic surgery in Argentina 
is unlikely as the family history of alterations in the BRCA 1 
and 2 genes remain unknown. We consider it essential that 
proper and adequate explanations are provided to BRCA gene 
mutation carriers with regard to the risk of cancer to facilitate 
the testing of relatives for genetic alterations and identification 
of BRCA1 mutation carriers, and subsequently, with the aid of 
professionals, to select the most appropriate preventive option.
In conclusion, the current study identified 21 polymorphisms 
in the 154 patients analyzed (14.49%). One patient was identi-
fied with a polymorphism in exon 2 (0.69%), four in exon 20 
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(2.76%), two in exon 11.1 (1.38%), four in exon 11.3 (2.76%), two 
in exon 11.5 (1.38%), one in exon 11.7 (0.69%), two in exon 11.8 
(1.38%), one in exon 11.10 (0.69%), one in exon 11.11 (0.69%) 
and three in exon 11.12 (2.07%). Polymorphisms are verified by 
sequencing to determine the type of mutation that characterizes 
them. The most prevalent polymorphisms of the BRAC1 gene 
in Argentinian patients were located in exon 11 (16 out of the 
21 patients; 76.20%; Table II). The objective of our next study 
is to evaluate the genetic susceptibility of healthy patients, as 
well as relatives of BRCA1-positive patients in Argentina, and 
to analyze 20 regions of the BRCA2 gene.
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